Table 4.
Primary Results for aPTT Controls Versus Anti-Xa Cohort.a
| Study Endpoints | aPTT | Anti-Xa | P Value |
|---|---|---|---|
| Time to therapeutic range (hours) | 24 (2.5-118.8) | 16 (0.8-69.3) | < .01 |
| Total time on heparin (hours) | 66.5 (14.5-370) | 61.5 (13-427) | .84 |
| Number of tests performed | 7 (1-34) | 6 (2-36) | .53 |
| Number of tests performed per 24 hours on heparin | 2.7 (1.3-6.6) | 2.7 (1-5.5) | .81 |
| Number of adjustments required | 4 (0-24) | 3 (0-16) | .06 |
| Number of adjustments required per 24 hours on heparin | 1.5 (0-5.3) | 1.2 (0-3.7) | .01 |
| Length of stay (days) | 6.5 (1.6-37.9) | 7.5 (1-43) | .46 |
| VTE | 1 (1) | 1 (1) | 1.00 |
| Bleeding | 4 (4) | 12 (11.9) | .07 |
| Mortality | 4 (4) | 0 (0) | .06 |
Abbreviation: aPTT, activated partial thromboplastin time; VTE, venous thromboembolism.
aData reported as medians (range).